Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

US8084457B2 · kind B2 · utility

Assignees

• Lead Discovery Center GmbH · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Axel Choidas · Herdecke, DE
• Alexander Backes · Munich, DE
• Matt Cotten · Banjul, GM
• Ola Engkvist · Vara, SE
• Beatrice Felber · Unterschleißheim, DE
• Achim Freisleben · Munich, DE
• Klaus Godl · Krailling, DE
• Zoltan Greff · Budapest, HU
• Peter Habenberger · Hersbruck, DE
• Doris Hafenbradl · Pullach, DE
• Christian Hartung · Essen, DE
• Thomas Herget · Planegg, DE
• Edmund Hoppe · Krailling, DE
• Bert Klebl · Dortmund, DE
• Andrea Missio · Montecchio Maggiore, IT
• Gerhard Müller · Krefeld, DE
• Wilfried Schwab · Altentreptow, DE
• Birgit Zech · Bogen, DE
• Jose Antonio Bravo · Haverhill, GB
• John Harris · Eynsford, GB
• Joelle Le · Stevenage, GB
• Jackie Macritchie · Saffron Walden, GB
• Vladimir Savic · Umka, RS
• Brad Sherborne · Lanark, GB
• Don Simpson · Haverhill, GB

Key dates

• Filing date: Sep 15, 2004
• Grant date: Dec 27, 2011
• Expiry date: Sep 15, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.